财中社11月13日电再鼎医药(09688/ZLAB)发布截至2024年9月30日的三季报。2024年第三季度,公司的产品收入净额为1.02亿美元,同比增长47%,主要得益于卫伟迦、则乐和纽再乐的销售增长。其中,卫伟迦的收入为2730万美元,而则乐和纽再乐的收入分别为4820万美元和1000万美元。研发支出为6600万美元,销售、一般及行政支出为6720万美元,经营亏损为6790万美元,净亏损为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.